Anchor Capital Advisors’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Anchor Capital Advisors’s Portfolio TARO Stock Details TARO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-8,160	Closed	-$944K	–	285
2018 Q2	$944K	Sell	8,160 -1,359	-14%	-$149K	0.03%	185
2018 Q1	$940K	Sell	9,519 -1,060	-10%	-$107K	0.03%	202
2017 Q4	$1.11M	Sell	10,579 -339	-3%	-$37.2K	0.04%	167
2017 Q3	$1.23M	Sell	10,918 -9,815	-47%	-$1.07M	0.04%	155
2017 Q2	$2.32M	Buy	20,733 +77	+0.4%	+$8.7K	0.08%	114
2017 Q1	$2.41M	Buy	20,656 +4,596	+29%	+$509K	0.08%	116
2016 Q4	$1.69M	Buy	16,060 +499	+3%	+$52.3K	0.06%	136
2016 Q3	$1.72M	Buy	15,561 +4,674	+43%	+$619K	0.06%	136
2016 Q2	$1.58M	Sell	10,887 -260	-2%	-$36.9K	0.04%	138
2016 Q1	$1.6M	Buy	+11,147	New	+$1.58M	0.04%	148

Other funds holding TARO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return

FCH

Freestone Capital Holdings Seattle, Washington $3.3B AUM 21.14% 1-Year Est. Return

Anchor Capital Advisors's TARO Position: Q3 2018 in Review

Anchor Capital Advisors sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q3 2018, closing a stake of 8,160 shares — an estimated $944K sold.

Anchor Capital Advisors first reported a position in TARO in Q1 2016 and held it in 10 quarters. The position peaked at $2.41M in Q1 2017. 114 funds tracked by Wall St. Rank hold TARO as of Q3 2018.

Anchor Capital Advisors reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q3 2018 after selling out during the quarter.
Anchor Capital Advisors sold 8,160 Taro Pharmaceutical Industries Ltd. shares in Q3 2018, an estimated $944K.
Anchor Capital Advisors first reported a position in Taro Pharmaceutical Industries Ltd. in Q1 2016 and held it in 10 quarters.
Anchor Capital Advisors's Taro Pharmaceutical Industries Ltd. position peaked at $2.41M in Q1 2017.
114 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q3 2018.

Based on Anchor Capital Advisors's 13F filing for Q3 2018, filed 31 Oct 2018.